Head-to-head · WeighScore
FormidableMD vs Omada Health
The verdict
FormidableMD takes it — 72.9/100 to 55.6/100.
FormidableMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FormidableMD is a physician-led, cash-pay telehealth practice based in Florida offering GLP-1 weight-loss treatment — semaglutide and tirzepatide in both FDA-approved and compounded forms, plus oral options…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FormidableMD | Omada Health |
|---|---|---|
| WeighScore | 72.9/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #74 | #436 |
| Semaglutide | $169/mo (1 mg dose, compounded) | Not disclosed |
| Tirzepatide | $199/mo (10 mg dose, compounded) | Not disclosed |
| Coverage | 1 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #74 · C
Strengths
- Transparent, published dose-by-dose pricing for semaglutide ($169-$269/mo) and tirzepatide ($199-$319/mo) with no membership or commitment
- Offers both FDA-approved and compounded GLP-1s (plus oral options) from 503A pharmacies, with a real provider at every visit
- Boutique physician-led model bundling labs, peptides, HRT/TRT and urgent care; FSA/HSA eligible
Where it loses points
- Florida-focused telehealth — availability outside FL is not advertised, so out-of-state access is uncertain
- Medication cost is on top of a $199 initial consultation and $99 follow-up visits (pay-per-visit, not an all-in monthly price)
- The 503A compounding pharmacy partner is not named on the site
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.